SCHEMBL13166761

SCHEMBL13166761

COCCNCc1cccc(C(C)(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 3/20 0.49
▸ BACE1 P56817 1/20 0.49
▸ SCN8A Q9UQD0 2/20 0.48
▸ KMT2A Q03164 2/20 0.46
▸ KDM4E B2RXH2 4/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ CHRM2 P08172 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ SCN2A Q99250 1/20 0.42
▸ MITF O75030 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ ADRA1D P25100 1/20 0.41
▸ ADRA1A P35348 1/20 0.41
▸ ADRA1B P35368 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13918962 0.81 BCHE (0.54) BCHEBACE1SCN8AKMT2AKDM4E
SCHEMBL13166771 0.81 BCHE (0.51) BCHEBACE1SCN8AKMT2AKDM4E
SCHEMBL12449590 0.80 L3MBTL1 (0.58) KMT2AKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL10272437 0.79 ALDH1A1 (0.56) BCHESCN8AKDM4EALDH1A1L3MBTL1
SCHEMBL13547854 0.78 TAAR1 (0.41) BCHEBACE1L3MBTL1HTT
SCHEMBL17664610 0.78 BCHE (0.51) BCHEBACE1SCN8AADRA1ADRD3
SCHEMBL13154916 0.78 BCHE (0.49) BCHEBACE1SCN8AKMT2AKDM4E
SCHEMBL18232504 0.78 MC4R (0.53) BCHEBACE1SCN8AKDM4ECHRM2
SCHEMBL3622330 0.78 CYP1A2 (0.60) KMT2AKDM4EALDH1A1L3MBTL1CHRM2
Hydrochloric Acid SCHEMBL7598195 0.76 L3MBTL1 (0.50) SCN8AKDM4EALDH1A1L3MBTL1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470850-B2 Inhibitors of VEGF receptor and HGF receptor signalling METHYLGENE INC. (CA) 2013-06-25 — — US disclosed
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling METHYLGENE, INC. 2010-09-30 — — US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 — — US disclosed
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling 92229129 QUEBEC INC. (CA) 2010-08-26 — — US disclosed
US-7772247-B2 Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor METHYLGENE INC. (CA) 2010-08-10 — — US disclosed
US-7772247-B2 Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor METHYLGENE INC. (CA) 2010-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249145-A1 Inhibitors of VEGF Receptor and HGF Receptor Signaling HGF, MET, FLT1 BCHE 4787/4885BACE1 1760/4885SCN8A 4608/4885
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling HGF, MET, FLT1 BCHE 4768/4885BACE1 1608/4885SCN8A 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback